Vanucizumab
- Generic Name
- Vanucizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1448221-05-3
- Unique Ingredient Identifier
- B800Z06O8K
- Background
Vanucizumab has been used in trials studying the treatment of ColoRectal Cancer and Advanced/Metastatic Solid Tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 94
- Registration Number
- NCT02665416
- Locations
- 🇳🇱
Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands
🇪🇸Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 197
- Registration Number
- NCT02141295
- Locations
- 🇬🇧
Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, United Kingdom
🇺🇸Fresno cCare, Fresno, California, United States
🇺🇸Oncology Hematology Care Inc, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath